Signet ring cell carcinoma of the Ampulla of Vater: outcomes of patients in the United States. HPB : the official journal of the International Hepato Pancreato Biliary Association Kinslow, C. J., May, M. S., Kozak, M., Pollom, E. L., Chang, D. T. 2020


BACKGROUND: Signet ring cell carcinoma (SRCC) of the ampulla of Vater is poorly understood, with approximately 22 reported cases. Our study sought to create a comprehensive review of cases in the United States.METHODS: We used the Surveillance, Epidemiology, and End Results Program to collect all cases of ampullary adenocarcinoma diagnosed between 2010 and 2015.RESULTS: The age-adjusted incidence rate of SRCC of the ampulla of Vater was 1.2 cases per 10,000,000 persons per year, with 50% more cases in males than females. We identified 3448 cases of adenocarcinoma of the ampulla of Vater, 81 of which were SRCC (2.3%). SRCC tended to present a later stage than other ampullary cancers, with median survival times of 17 vs. 25 months, (p=0.07). Survival was significantly worse for SRCC when accounting for other clinical features (HR 1.46, p=0.01). Factors portending worse prognosis in SRCC of the ampulla of Vater were advanced age, late stage and lack of surgical intervention.CONCLUSION: Our study represents the largest study of SRCC of the ampulla of Vater to date. SRCC has a poorer prognosis compared with other ampullary cancers. Optimal treatment regimen is the most important future area of study.

View details for DOI 10.1016/j.hpb.2020.03.024

View details for PubMedID 32317226